Intravesical Bacille Calmette-Guérin Therapy for Non-Muscle-Invasive Bladder Cancer: Effects of Concurrent Statin Therapy

Skolarus, Ted A., Lee, Eugene W., Virgo, Katherine S., Katz, Matthew D., Hudson, M’Liss A., Kibel, Adam S. and Grubb III, Robert L. (2009) Intravesical Bacille Calmette-Guérin Therapy for Non-Muscle-Invasive Bladder Cancer: Effects of Concurrent Statin Therapy. Journal of the American College of Surgeons, 209 2: 248-253. doi:10.1016/j.jamcollsurg.2009.04.014


Author Skolarus, Ted A.
Lee, Eugene W.
Virgo, Katherine S.
Katz, Matthew D.
Hudson, M’Liss A.
Kibel, Adam S.
Grubb III, Robert L.
Title Intravesical Bacille Calmette-Guérin Therapy for Non-Muscle-Invasive Bladder Cancer: Effects of Concurrent Statin Therapy
Journal name Journal of the American College of Surgeons   Check publisher's open access policy
ISSN 1072-7515
1879-1190
Publication date 2009-01-01
Sub-type Article (original research)
DOI 10.1016/j.jamcollsurg.2009.04.014
Open Access Status Not Open Access
Volume 209
Issue 2
Start page 248
End page 253
Total pages 6
Place of publication Philadelphia, PA, United States
Publisher Elsevier
Formatted abstract
Background: Recent studies provide conflicting evidence about the association of statin use and decreased efficacy of intravesical bacille Calmette-Guérin (BCG) therapy for bladder cancer. Because statin drugs have immunomodulatory properties that could reduce the effectiveness of BCG, we investigated whether concurrent use of statin drugs was associated with worsened clinical outcomes in patients undergoing BCG treatment for non-muscle-invasive bladder cancer.

Study Design: We retrospectively analyzed records of 120 patients undergoing BCG treatment during 1997 through 2007 at a single Department of Veterans Affairs Medical Center. Tumor-progression events, total recurrences, disease-specific and overall mortality were the outcomes relative to statin use. Fisher's exact, Student's t-tests, and logistic regression were used to compare the groups.

Results: Among the 90 evaluable patients, there were no significant differences between groups with regard to tumor grade and stage distribution or smoking status. Statins were used during BCG therapy by 47.8% of patients. Comparing patients with no use versus use of statins, 8.5% versus 11.6% had local tumor progression (p = 0.44); 10.6% versus 9.3% underwent cystectomy, chemotherapy, or radiation therapy (p = 0.56); and metastatic disease developed in 6.7% versus 11.6% (p = 0.33). Of the 27 patients who died of any cause, 12.5% (2 of 16) versus 27.3% (3 of 11) in the nonstatin versus statin groups, respectively, died of disease (p = 0.32).

Conclusions: Concurrent statin use was not associated with adverse outcomes for patients undergoing BCG treatment for bladder cancer. While statins have a plausible biologic mechanism to reduce BCG efficacy, no differences were seen in this small pilot study. 
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 10 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 10 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Jan 2014, 21:24:10 EST by Ms Kate Rowe on behalf of School of Medicine